Interim Analysis of a Randomized Phase II Study of the Novel Ii-Key Hybrid HER2/NeuPeptide (AE37) Vaccine To Prevent Breast Cancer Recurrence: United States Military Cancer Institute Clinical Trials Group Study I-05.

Mapping Intimacies ◽

10.1158/0008-5472.sabcs-09-3183 ◽

2009 ◽

Author(s):

G. Peoples ◽

S. Perez ◽

G. Clifton ◽

J. Holmes ◽

K. Georgakopoulou ◽

...

Keyword(s):

Breast Cancer ◽

United States ◽

Clinical Trials ◽

Phase Ii ◽

Interim Analysis ◽

Phase Ii Study ◽

Cancer Recurrence ◽

The Novel ◽

United States Military ◽

Randomized Phase Ii

Download Full-text

Interim Analysis of a Randomized Phase II Study of the Novel HER2/NeuPeptide (GP2) Vaccine To Prevent Breast Cancer Recurrence: United States Military Cancer Institute Clinical Trials Group Study I-05.

10.1158/0008-5472.sabcs-09-5110 ◽

2009 ◽

Cited By ~ 3

Author(s):

G. Clifton ◽

J. Holmes ◽

S. Perez ◽

D. Lorentz ◽

K. Georgakopoulou ◽

...

Keyword(s):

Breast Cancer ◽

United States ◽

Clinical Trials ◽

Phase Ii ◽

Interim Analysis ◽

Phase Ii Study ◽

Cancer Recurrence ◽

The Novel ◽

United States Military ◽

Randomized Phase Ii

Download Full-text

Abstract CT162: Pre-specified interim analysis in a prospective, randomized phase II trial of trastuzumab vs trastuzumab + NeuVax to prevent breast cancer recurrence in HER2+ breast cancer patients

10.1158/1538-7445.am2017-ct162 ◽

2017 ◽

Author(s):

Kaitlin M. Peace ◽

Jennifer K. Litton ◽

Rashmi Murthy ◽

Timothy J. Vreeland ◽

Diane F. Hale ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Interim Analysis ◽

Phase Ii Trial ◽

Cancer Recurrence ◽

Breast Cancer Recurrence ◽

Breast Cancer Patients ◽

Her2 Breast Cancer ◽

Randomized Phase Ii

Download Full-text

Faculty of 1000 evaluation for Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718021759.793480257 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Progesterone Receptor ◽

Phase Ii ◽

Phase Ii Study ◽

Second Line ◽

Second Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii ◽

Positive Breast Cancer

Download Full-text

Faculty Opinions recommendation of Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734565867.793581155 ◽

2020 ◽

Author(s):

David Potter

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Neoadjuvant Therapy ◽

Early Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Estrogen Receptor Positive

Download Full-text

346 Taxol or doxorubicin as first line chemotherapy in advanced breast cancer (ABC). A prospective randomized phase II study with crossover

European Journal of Cancer ◽

10.1016/0959-8049(95)95599-2 ◽

1995 ◽

Vol 31 ◽

pp. S75 ◽

Cited By ~ 1

Author(s):

R. Paridaens ◽

P. Bruning ◽

F. Calabresi ◽

A. Awada ◽

J.A. Roy ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Breast ◽

First Line ◽

Randomized Phase Ii ◽

Line Chemotherapy

Download Full-text

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

Annals of Oncology ◽

10.1093/annonc/mdx505 ◽

2018 ◽

Vol 29 (1) ◽

pp. 154-161 ◽

Cited By ~ 70

Author(s):

H.S. Han ◽

V. Diéras ◽

M. Robson ◽

M. Palácová ◽

P.K. Marcom ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Locally Recurrent

Download Full-text

Randomized phase II study of single-agent epirubicin +/— verapamil in patients with advanced metastatic breast cancer

Annals of Oncology ◽

10.1093/oxfordjournals.annonc.a058356 ◽

1993 ◽

Vol 4 (1) ◽

pp. 45-50 ◽

Cited By ~ 35

Author(s):

K. Mross ◽

C. Bohn ◽

L. Edler ◽

W. Jonat ◽

W. Queisser ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Single Agent ◽

Metastatic Breast ◽

Randomized Phase Ii

Download Full-text

START: A randomized phase II study in patients with triple negative, androgen receptor positive locally recurrent (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine (UCBG-306)

Annals of Oncology ◽

10.1093/annonc/mdy272.356 ◽

2018 ◽

Vol 29 ◽

pp. viii120 ◽

Cited By ~ 1

Author(s):

H. Bonnefoi ◽

C. Levy ◽

G. MacGrogan ◽

T. Grellety ◽

B. Asselain ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Androgen Receptor ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Study ◽

Metastatic Breast ◽

Randomized Phase Ii ◽

Locally Recurrent

Download Full-text

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

Annals of Oncology ◽

10.1093/annonc/mds132 ◽

2012 ◽

Vol 23 (12) ◽

pp. 3069-3074 ◽

Cited By ~ 94

Author(s):

E. Alba ◽

L. Calvo ◽

J. Albanell ◽

J.R. De la Haba ◽

A. Arcusa Lanza ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Neoadjuvant Treatment ◽

Luminal Breast Cancer ◽

Breast Cancer Patients ◽

Randomized Phase Ii

Download Full-text

Is It Important to Adapt Neoadjuvant Chemotherapy to the Visible Clinical Response? An Open Randomized Phase II Study Comparing Response‐Guided and Standard Treatments in HER2‐Negative Operable Breast Cancer

The Oncologist ◽

10.1634/theoncologist.2014-0400 ◽

2015 ◽

Vol 20 (3) ◽

pp. 243-244 ◽

Cited By ~ 1

Author(s):

Qian Wang‐Lopez ◽

Marie‐Ange Mouret‐Reynier ◽

Aude‐Marie Savoye ◽

Catherine Abrial ◽

Fabrice Kwiatkowski ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Clinical Response ◽

Phase Ii ◽

Phase Ii Study ◽

Operable Breast Cancer ◽

Randomized Phase Ii

Download Full-text